Evidence-Based Cannabinoid Education

Non-Intoxicating Cannabinoids

CBD, CBG, CBC, and CBN each work through distinct mechanisms — enabling a targeted, precision approach to cannabinoid therapy without intoxication.

CBD — The Versatile Foundation

CBG — The Mother Cannabinoid

CBC — The Neurogenesis Cannabinoid

CBN — The Degradation Cannabinoid

Medical disclaimer: This guide is for educational purposes only. Dosage ranges are based on published literature and are not clinical recommendations. Consult a healthcare provider before using any cannabinoid product, especially if you take prescription medications or have a medical condition.

CBD

Cannabidiol

The Versatile Foundation

The most researched non-intoxicating cannabinoid — FDA-approved for epilepsy

Broad-spectrum therapeutic activity via serotonin, TRP channels, and indirect endocannabinoid enhancement.

Non-intoxicating

Hemp-derived CBD federally legal (2018 Farm Bill)

1–20% in cannabis; up to 20%+ in hemp cultivars

What makes CBD unique

Broadest evidence base of any non-intoxicating cannabinoid. Only one with FDA approval. Most studied for anxiety, epilepsy, and inflammation. Potent CYP450 inhibitor — highest drug interaction risk of the four.

Only FDA-approved plant-derived cannabinoid (Epidiolex, 2018) — for Dravet syndrome, LGS, and TSC.

WHO Expert Committee (2017): no abuse potential, no evidence of harm at therapeutic doses.

Highest drug interaction risk of all non-intoxicating cannabinoids — inhibits CYP2C9, CYP2C19, CYP3A4.

Bioavailability increases up to 3× when taken with a high-fat meal.

Does not directly activate CB1 or CB2 receptors at therapeutic doses.

Cannabidiol is the most extensively studied non-intoxicating cannabinoid and the only plant-derived cannabinoid with FDA approval (Epidiolex, 2018). It does not produce intoxication at any dose and has a well-characterized safety profile. CBD works through multiple mechanisms simultaneously — making it a versatile foundation for a targeted cannabinoid approach. Its most robust evidence is for treatment-resistant epilepsy, anxiety, and as an adjunct for inflammation.

Biosynthesis

Synthesized from CBGA via CBDA synthase → CBDA → decarboxylation → CBD

Natural Abundance

1–20% in cannabis; up to 20%+ in hemp cultivars

Primary Receptors & Targets

5-HT1A (agonist — anxiolytic, antidepressant)
TRPV1 (agonist — analgesic, anti-inflammatory)
GPR55 (antagonist — anticonvulsant)
FAAH inhibition (raises anandamide — indirect ECS enhancement)
CB1/CB2 (weak/indirect — no direct agonism at therapeutic doses)

Legal Status

Hemp-derived CBD federally legal (2018 Farm Bill). Epidiolex is Schedule V. OTC CBD exists in a regulatory gray area — FDA has not approved it as a dietary supplement.

Evidence Rating Scale

SubstantialMultiple high-quality RCTs

ModerateSome RCTs or strong observational data

LimitedSmall trials or inconsistent results

PreclinicalAnimal/cell studies only

InsufficientNo meaningful evidence

The critical takeaway: CBD has the strongest human evidence base. CBG, CBC, and CBN have promising preclinical data but no completed human RCTs for most indications. This gap between marketing claims and clinical evidence is important for informed decision-making.

Last Reviewed: November 2025